3rd ProCAncer-I Project Dissemination Event in Athens

An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum: In Europe, prostate cancer (PC) is the second most frequent type of cancer in men and the third most lethal. Current clinical practices lead to overdiagnosis and overtreatment, necessitating more effective tools for discriminating between aggressive and non-aggressive disease. The EU-funded ProCAncer-I project proposes to develop advanced artificial intelligence models to address unmet clinical needs: diagnosis, metastases detection and prediction of response to treatment. To achieve this, partners will generate a large interoperable repository of health images, and a scalable high-performance computing platform hosting the largest collection of PC Magnetic Resonance Images used for developing robust PC AI models. To ensure the rapid clinical implementation of the models developed, the project’s partners will robustly monitor performance, accuracy and reproducibility. 

Welcome by Coordinating Team

We are very glad to lead a very ambitious and health-driven project that could end to alleviating and helping thousands of men to tackle prostate cancer in a more personalized way supporting a better quality of life

The Coordinating Team

Manolis Tsiknakis

Prof. Manolis Tsiknakis
(Coordinator)

Dr. Nikolaos Papanikolaou
(Scientific Manager)

Prof. Kostas Marias
(Technical Manager)

Prof. Daniele Regge
(Clinical Manager)

The ProCAncer-I project is one of the founding projects of the FUTURE-AI.

FUTURE-AI is an international, multi-stakeholder initiative for defining and maintaining concrete guidelines that will facilitate the design, development, validation, and deployment of trustworthy AI solutions in medical imaging based on six guiding principles: Fairness, Universality, Traceability, Usability, Robustness, and Explainability.

Project Information

Months (Duration)

Euros (Total Budget )

Grant Agreement Nr.

Funded

This project has received funding from the European Union’s Horizon 2020 research and innovation programme

|

Topic

DT-TDS-05-2020:
AI for Health Imaging

Highlights

ProCAncer-I at the EMUC24 in Lisbon

ProCAncer-I at the EMUC24 in Lisbon

The progress of major trials, the advent of artificial intelligence (AI), and interdisciplinary best practices will comprise the scientific programme of the 16th European Multidisciplinary Congress on Urological Cancers (EMUC24), which will take place from 7 to 10...

Third Dissemination Event of the ProCAncer-I Project in Athens

Third Dissemination Event of the ProCAncer-I Project in Athens

ProCAncer-I organised the 3rd Dissemination Event of the project at the 21st IEEE International Symposium on Biomedical Imaging, held in Athens, Greece, May 27-30, 2024. During the symposium, ProCAncer-I organised the Workshop “Integrating imaging Data and AI models...

AI in PCa imaging : The current status and future perspectives

AI in PCa imaging : The current status and future perspectives

Ιn recent years, magnetic resonance imaging (MRI) has transformed the prostate cancer (PCa) diagnostic pathway, based on the evidence of multiple high-level evidence studies (refs 4M, MRI first, and PROMIS). Taken together, the evidence indicates that prostate MRI...

Open Call To Include New Beneficiaries Into The EUCAIM Consortium

Open Call To Include New Beneficiaries Into The EUCAIM Consortium

The EUCAIM project is launching an open call for new beneficiaries to join the consortium. The objective of the EUCAIM open call is to: i) onboard new cancer image data holders, increasing the geographic dimensions, data modalities or cancer targets, and  ii) include...

Twitter feed is not available at the moment.

Stay in touch!